Logo image of MBII

Marrone Bio Innovations Inc (MBII) Stock Fundamental Analysis

NASDAQ:MBII - Nasdaq - US57165B1061 - Common Stock

0.7981  -0.2 (-20.19%)

After market: 0.81 +0.01 (+1.49%)

Fundamental Rating

1

MBII gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 85 industry peers in the Chemicals industry. Both the profitability and financial health of MBII have multiple concerns. MBII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MBII has reported negative net income.
MBII Yearly Net Income VS EBIT VS OCF VS FCFMBII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -27.42%
ROE N/A
ROIC -39.84%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBII Yearly ROA, ROE, ROICMBII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 500 1K 1.5K 2K

1.3 Margins

Industry RankSector Rank
OM -39.16%
PM (TTM) -47.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBII Yearly Profit, Operating, Gross MarginsMBII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

0

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MBII is destroying value.
Compared to 1 year ago, MBII has more shares outstanding
Compared to 1 year ago, MBII has a worse debt to assets ratio.
MBII Yearly Shares OutstandingMBII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M
MBII Yearly Total Debt VS Total AssetsMBII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -5.45, we must say that MBII is in the distress zone and has some risk of bankruptcy.
MBII has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -5.45
ROIC/WACC-4.36
WACC9.13%
MBII Yearly LT Debt VS Equity VS FCFMBII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M

2.3 Liquidity

MBII has a Current Ratio of 0.79. This is a bad value and indicates that MBII is not financially healthy enough and could expect problems in meeting its short term obligations.
MBII has a Quick Ratio of 0.79. This is a bad value and indicates that MBII is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.55
MBII Yearly Current Assets VS Current LiabilitesMBII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

MBII shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
The Revenue has grown by 11.59% in the past year. This is quite good.
The Revenue has been growing by 25.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)11.59%
Revenue growth 3Y27.82%
Revenue growth 5Y25.84%
Sales Q2Q%0.54%

3.2 Future

MBII is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.93% yearly.
MBII is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.33% yearly.
EPS Next Y-7.1%
EPS Next 2Y34.01%
EPS Next 3Y21.55%
EPS Next 5Y9.93%
Revenue Next Year29.1%
Revenue Next 2Y27.43%
Revenue Next 3Y27.21%
Revenue Next 5Y26.33%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MBII Yearly Revenue VS EstimatesMBII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
MBII Yearly EPS VS EstimatesMBII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MBII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBII. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBII Price Earnings VS Forward Price EarningsMBII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -12.13
MBII Per share dataMBII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2

4.3 Compensation for Growth

MBII's earnings are expected to grow with 21.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.01%
EPS Next 3Y21.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Marrone Bio Innovations Inc

NASDAQ:MBII (7/12/2022, 8:00:01 PM)

After market: 0.81 +0.01 (+1.49%)

0.7981

-0.2 (-20.19%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-11 2022-05-11/amc
Earnings (Next)08-15 2022-08-15/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners5.35%
Ins Owner Change0%
Market Cap145.56M
Analysts78
Price Target1.4 (75.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.28
P/FCF N/A
P/OCF N/A
P/B 6.36
P/tB N/A
EV/EBITDA -12.13
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.24
BVpS0.13
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.42%
ROE N/A
ROCE N/A
ROIC -39.84%
ROICexc N/A
ROICexgc -147.33%
OM -39.16%
PM (TTM) -47.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.55
Altman-Z -5.45
F-Score3
WACC9.13%
ROIC/WACC-4.36
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-7.1%
EPS Next 2Y34.01%
EPS Next 3Y21.55%
EPS Next 5Y9.93%
Revenue 1Y (TTM)11.59%
Revenue growth 3Y27.82%
Revenue growth 5Y25.84%
Sales Q2Q%0.54%
Revenue Next Year29.1%
Revenue Next 2Y27.43%
Revenue Next 3Y27.21%
Revenue Next 5Y26.33%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A